Rxivist logo

Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin and provides insights into microtubule dynamic instability

By Jianhong Yang, Yamei Yu, Yong Li, Haoyu Ye, Wei Yan, Lu Niu, Yunhua Zheng, Zhoufeng Wang, Zhuang Yang, Heying Pei, Haoche Wei, Min Zhao, Jiaolin Wen, Linyu Yang, Liang Ouyang, Yuquan Wei, Qiang Chen, Weimin Li, Lijuan Chen

Posted 11 Sep 2020
bioRxiv DOI: 10.1101/2020.09.11.293563

Microtubule, composed of αβ-tubulin heterodimers, remains as one of the most popular anticancer targets for decades. To date, anti-microtubule drugs mainly target β-tubulin to inhibit microtubule dynamic instability (MDI) while agents binding to α-tubulin are less well characterized and also the molecular mechanism of MDI is far from being articulated. Cevipabulin, an oral microtubule-active antitumor clinical candidate, is widely accepted as a microtubule stabilizing agent (MSA) but binds to the microtubule-destabilization vinblastine site on β-tubulin and this unusual phenomenon has so far failed to be explained. Our X-ray crystallography study reveals that, in addition binding to the vinblastine site, cevipabulin also binds to a novel site on α-tubulin (named the seventh site) which located at the region spatially corresponding to the vinblastine site on β-tubulin. Interestingly, cevipabulin exhibits two unique site-dependent functions. Cevipabulin binding to the seventh site promotes tubulin degradation through interaction of the non-exchengeable GTP to reduce tubulin stability. Cevipabulin binding to the vinblastine site enhances longitudinal interactions but inhibits lateral interactions of tubulins, thus inducing tubulin protofilament polymerization (but not microtubule polymerization like MSAs), and then tangling into irregular tubulin aggregates. Importantly, the tubulin-cevipabulin structure is an intermediate between “bent” and “straight” tubulins and the involved bent-to-straight conformation change will be helpful to fully understand the molecular mechanism of tubulin assembly. Our findings confirm cevipabulin is not an MSA and shed light on the development of a new generation of anti-microtubule drugs targeting the novel site on α-tubulin and also provide new insights into MDI. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 311 times
  • Download rankings, all-time:
    • Site-wide: 97,591
    • In cell biology: 4,488
  • Year to date:
    • Site-wide: 36,398
  • Since beginning of last month:
    • Site-wide: None

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide